Global Briefs: AstraZeneca, Roche, Takeda & More
A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring AstraZeneca, Roche, Takeda, and SK bioscience. Highlights below.
For the latest news roundup on small and Emerging Pharma companies, see Biotech Briefs.
Partnering News
* AstraZeneca, CSPC Pharmaceuticals in $4.7-Bn Obesity & Diabetes Drug Pact
* Roche, SanegeneBio in $1.7-Bn RNAi Development Pact
* SK bioscience, Gates MRI in Respiratory Drug Pact
Reorganization
* Takeda To Change Organizational Structure & Leadership Team
Pipeline & Product Updates
* AstraZeneca Gets Complete Response Letter for Lupus Biologic
General
* US Gov’t Launches $100-M Small-Molecule Antiviral Initiative
Partnering News
AstraZeneca, CSPC Pharmaceuticals in $4.7-Bn Obesity & Diabetes Drug Pact
AstraZeneca has entered an agreement with CSPC Pharmaceuticals, a Shijiazhuang, China-based bio/pharmaceutical company, to advance the development of multiple therapies for obesity and Type 2 diabetes across eight programs, in a deal worth up to $4.7 billion ($1.2 billion upfront and $3.5 billion in milestone payments).
Under the agreement, the companies will initially progress four programs, which use CSPC’s advanced AI-driven peptide drug-discovery platform and its proprietary LiquidGel once-monthly dosing platform technology. AstraZeneca will receive exclusive global rights outside of China to CSPC’s once-monthly injectable weight-management portfolio, comprising one clinical-ready asset, SYH2082, a long-acting GLP1R/GIPR agonist progressing into Phase I and three preclinical programs with differing mechanisms designed to provide extended therapeutic benefits for people living with obesity and weight-related conditions.
Under the agreement, CSPC will receive an upfront payment of $1.2 billion from AstraZeneca. CSPC is also eligible to receive development and regulatory milestones of up to $3.5 billion across all programs. CSPC will also be eligible for further commercialization and sales milestones plus tiered royalties. The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory clearances.
Source: AstraZeneca
Roche, SanegeneBio in $1.7-Bn RNAi Development Pact
Roche’s Genentech has entered an agreement with SanegeneBio, a clinical-stage bio/pharmaceutical company developing RNAi therapeutics, to advance one of SanegeneBio’s RNAi programs based on its proprietary RNAi platform, in a deal worth up to $1.7 billion ($200 million upfront and $1.5 billion in milestone payments).
Under the agreement, SanegeneBio grants Genentech exclusive worldwide rights to develop and commercialize the program. SanegeneBio will be responsible for early development activities, and Genentech will subsequently lead all future clinical development and commercialization activities.
Under the agreement, SanegeneBio will receive an upfront payment of $200 million and will be eligible to receive development and commercialization milestone payments, totaling up to $1.5 billion, as well as tiered royalties on potential future product sales.
Source: SanegeneBio
SK bioscience, Gates MRI in Respiratory Drug Pact
SK bioscience has entered into a license agreement with the Gates Medical Research Institute (Gates MRI), a nonprofit medical research organization and an affiliate of the Gates Foundation, to develop and commercialize a clinical-stage monoclonal antibody (mAb) candidate as a prophylactic treatment for the prevention of respiratory syncytial virus.
Under the agreement, SK bioscience has secured exclusive worldwide rights to commercialize the candidate mAb if proven safe and effective, including in high-income countries, with non-exclusive supply in India and Gavi-eligible countries. Gavi is an international public–private partnership with a mission to improve access to vaccines in low-income countries.
In addition, the agreement includes global access commitments by SK bioscience that are aligned with the Gates MRI’s mission to advance equitable access to health technologies for populations most in need. In parallel, the company plans to advance large-scale manufacturing process development to enable affordable supply to low-resource settings.
Source: SK bioscience
Reorganization
Takeda To Change Organizational Structure & Leadership Team
Takeda has announced changes to its executive leadership team and organizational structure, effective at the start of the company’s next fiscal year, April 1, 2026.
Key changes include the formation of new groups:
- The International Business Unit (IBU) will directly oversee all markets outside of the US. For the Japan Pharma Business Unit (JPBU), execution and financial planning will be managed through IBU, which will provide JPBU additional resources and ensure alignment. Asuka Miyabashira remains President of the JPBU and Japan region head, overseeing the company’s second largest market. The newly established IBU will be led by Giles Platford, current President of the Plasma-Derived Therapies Business Unit. The company is recruiting a new President of the Plasma-Derived Therapies Business Unit (PDT).
- Strategy & Portfolio Development (SPD) will be established to drive integration and alignment of therapeutic area and corporate strategy, portfolio decision-making, new product planning and business development. The company is recruiting a new strategy and portfolio development officer.
- The Transformation Office will connect transformation across the company, including AI initiatives. This group will be led by Lauren Duprey, who is the current Chief Human Resources Officer (CHRO). The company is recruiting a new CHRO.
Alongside the new groups, the company also announced changes to existing groups:
- Global Supply & Quality will be led by current Global Quality Officer Elaine Shannon.
- Global Medical will be elevated to an executive team function and continue to be led by Chief Medical Officer Awny Farajallah.
- Global Legal, Ethics & Compliance will be led by current Global General Counsel Natalie Furney.
- The company is recruiting a head of Global Communications & Governance.
Source: Takeda
Pipeline & Product Updates
AstraZeneca Gets Complete Response Letter for Lupus Biologic
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the biologics license application for AstraZeneca’s Saphnelo (anifrolumab) for subcutaneous administration in adult patients with systemic lupus erythematosus. AstraZeneca stated that it has subsequently provided the information requested in the CRL and is committed to working with FDA to progress the application as quickly as possible.
A decision from the FDA on the updated application for Saphnelo SC is expected in the first half of 2026.
Source: AstraZeneca
General
US Gov’t Launches $100-M Small-Molecule Antiviral Initiative
The US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services, has launched a $100-million small-molecule antiviral initiative aimed at identifying safe and effective broad-spectrum small molecules that have the potential to advance into clinical trials and achieve US regulatory approval. The goal of this competition is to advance the development of antivirals that strengthen the therapeutic pipeline and address gaps in strategic preparedness in partnership with innovators.
The initiative is split across four phases: the concept stage, hit-to-lead, lead optimization, and IND readiness. The current stage, the concept stage has a total prize pool of $20 million, with up to eight targets each receiving $2.5 million each. The application timeline for this stage is from February 2 – March 11, 2026. The hit to lead stage, anticipated to go live in the summer of 2026, has a prize pool of $36 million, with up to six targets receiving $6 million each. The lead optimization and investigational new drug (IND) readiness phases are anticipated to go live in early 2028 and early 2030, respectively. The prize pool for those stages is to be announced, but will have at least four targets and two targets, respectively.
